A good Oncotype DX score is 25 or lower. Scores in this range indicate a lower risk of the cancer returning and generally mean you can skip chemotherapy and be treated with hormone therapy alone. The test produces a recurrence score from 0 to 100, with lower numbers reflecting less aggressive tumor biology. Where your specific number falls within that range, and what it means for your treatment, depends on your age, menopausal status, and whether cancer has spread to any lymph nodes.
How the Score Scale Works
The Oncotype DX test analyzes the activity of 21 genes in your breast tumor tissue and generates a single recurrence score between 0 and 100. Memorial Sloan Kettering Cancer Center defines a low recurrence score as 0 to 25 and a high recurrence score as 26 to 100. This is the current two-tier system used in clinical practice, replacing an older three-tier model that had a separate “intermediate” category.
The score estimates two things: how likely your cancer is to come back within the next 9 to 10 years, and how much you would benefit from adding chemotherapy to hormone therapy. A score of 0 to 10 carries the lowest recurrence risk. In the landmark TAILORx trial, women with scores in this range who took only hormone therapy had a recurrence rate of just 3% at nine years. Scores from 11 to 25 still fall in the low-risk category, though recurrence rates are modestly higher.
Who the Test Is For
The Oncotype DX test isn’t ordered for every breast cancer diagnosis. It’s designed for a specific group: people with early-stage invasive breast cancer that is estrogen receptor-positive and HER2-negative, with a tumor larger than 5 millimeters. If you’re premenopausal, the test is typically used when cancer hasn’t spread to the lymph nodes (or only tiny deposits, smaller than 2 millimeters, are found). If you’re postmenopausal, it can also be used when up to three lymph nodes are involved.
The test exists to answer one practical question: will chemotherapy meaningfully reduce your risk of recurrence, or can hormone therapy alone do the job? If the answer is hormone therapy alone, you avoid months of chemotherapy and its side effects without compromising your outcome.
Why Age and Menopause Status Change the Cutoffs
The headline number of 25 doesn’t tell the full story for everyone. Your age and whether you’ve gone through menopause shift how oncologists interpret scores in the middle range.
For postmenopausal women with no lymph node involvement, a score of 25 or below is a clear signal that chemotherapy can be safely skipped. The TAILORx trial showed that hormone therapy alone performed just as well as the combination of chemotherapy and hormone therapy in this group. The same holds true for postmenopausal women with one to three positive lymph nodes. The RxPONDER trial confirmed that their five-year outcomes were essentially identical whether they received chemotherapy or not, as long as their score was 25 or below.
For premenopausal women, the picture is more nuanced. If your score is 0 to 15 and you have no lymph node involvement, you’re in solid territory to skip chemotherapy. But if your score falls between 16 and 25, there’s a gray zone. Subgroup analysis from TAILORx found that younger women in this range had slightly lower recurrence rates when chemotherapy was added. The benefit is small in absolute terms, but it’s real enough that your oncologist will likely want to discuss it with you rather than dismiss chemotherapy outright.
The gray zone gets even wider for premenopausal women with one to three positive lymph nodes. The RxPONDER trial found a roughly 5% absolute benefit from chemotherapy for premenopausal women across the entire 0 to 25 score range, regardless of the specific number. That means even a score of 5 doesn’t automatically rule out a conversation about chemotherapy if you’re premenopausal with positive nodes. Whether that 5% difference is meaningful to you is a personal decision, and factors like the number of nodes involved and the type of breast cancer play into the discussion.
What a High Score Means
A score of 26 or higher is considered high risk. Chemotherapy provides a clear, measurable benefit for people in this range. In the TAILORx trial, women with high recurrence scores who received both chemotherapy and hormone therapy had strong outcomes: more than 90% had no distant recurrence at five years, and 95.9% were still alive. Researchers estimated that without chemotherapy, only about 78.8% would have been recurrence-free at five years. That gap of roughly 12 percentage points represents the real-world value of chemotherapy for high-score patients.
Higher scores within this range generally reflect more aggressive tumor biology, though the test doesn’t create a sharp gradient between, say, 30 and 50. The key clinical distinction is above or below 26.
DCIS Scores Use a Different Scale
If you have ductal carcinoma in situ (DCIS), a non-invasive form of breast cancer, there’s a separate version of the Oncotype DX test with entirely different score ranges. A low-risk DCIS score is below 39, intermediate risk falls between 39 and 54, and high risk is above 54. These numbers help guide decisions about radiation therapy after surgery rather than chemotherapy decisions. Don’t compare DCIS scores to invasive cancer scores, as they measure different things on different scales.
Putting Your Score in Context
A single number can feel like it defines your prognosis, but the recurrence score is one piece of a larger picture. Tumor size, lymph node status, cancer grade, and your age all factor into treatment planning alongside the Oncotype result. Two people with a score of 20 might face different recommendations if one is a 35-year-old with a positive lymph node and the other is a 62-year-old with node-negative disease.
The most useful way to think about your score is as a tool that narrows uncertainty. For the majority of women with early-stage, hormone receptor-positive breast cancer, the test confirms what clinical trials have shown: that hormone therapy alone provides excellent long-term outcomes, and chemotherapy can be reserved for the smaller group of patients whose tumor biology makes it worthwhile.